M.D.
ST
Saghmos Therapeutics
The startup is conducting a Phase 3 clinical trial for a biopharmaceutical product aimed at reducing the risk of Major Adverse Cardiac and Kidney Events following percutaneous coronary intervention procedures. This addresses the critical need for improved treatment options for patients facing life-threatening cardiovascular and renal complications.
- Biotechnology
Updated 6 months ago
Funding
Raised to date
$3.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup is conducting a Phase 3 clinical trial for a biopharmaceutical product aimed at reducing the risk of Major Adverse Cardiac and Kidney Events following percutaneous coronary intervention procedures. This addresses the critical need for improved treatment options for patients facing life-threatening cardiovascular and renal complications.